This Dividend Stock Pays You 12 Times Per Year. Here's What a $25,000 Investment Deposits Each Month.

Healthpeak Properties offers a monthly dividend of just over $0.1033 per share, equating to a 6.02% yield at roughly $20.30 per share; a $25,000 investment would generate just over $127 in monthly income. The healthcare-focused REIT has risen more than 26% in 2026, versus a roughly 12.5% gain for the S&P 500, supported by the sector's relatively defensive demand profile. The article notes, however, that Healthpeak was not included in Motley Fool Stock Advisor's latest top-10 recommendations.

Analysis

DOC’s income narrative is less important than its duration exposure: after a sharp rerating, incremental upside depends on Treasury yields falling further and on management converting leasing activity into same-store NOI growth without meaningful concessions. A monthly distribution does not change the underlying payout burden; the relevant diligence items are normalized FFO payout ratio, tenant retention, development spend, and whether dispositions are required to fund the dividend or debt maturities. The near-term risk is that retail demand for yield has already pulled forward valuation expansion, leaving DOC vulnerable to even a modest backup in the 10-year Treasury.

The more differentiated setup is within healthcare real estate. Outpatient and medical-office demand should prove more resilient than traditional office, but lab/life-science exposure remains tied to biotech funding and tenant expansion decisions; this can create a lagged leasing and bad-debt risk despite defensive healthcare demand. Over 1-3 months, earnings guidance, leasing spreads, and the next CPI/Fed-rate repricing matter more than dividend frequency. Over 6-18 months, lower rates would improve refinancing economics and private-market asset values, while persistently elevated rates would expose any mismatch between the stated yield and sustainable FFO growth.

Contrarian view: the market may be treating DOC as a bond substitute just as its equity duration has risen following the rally. If the 10-year moves higher by 25-40bp or guidance implies flat-to-negative same-store NOI, the stock can underperform VNQ despite its perceived defensiveness; healthcare tenancy is not a complete hedge against capital-cost pressure.

Key Decisions for Investors

• Do not chase DOC at current momentum; establish a watch level only after the next earnings release confirms normalized FFO coverage of the distribution and stable-to-positive same-store NOI guidance. A guidance cut or weakening leasing spreads falsifies the long case.
• For rate-cut exposure, prefer a risk-controlled relative position: long DOC / short VNQ over a 1-3 month horizon only if the 10-year Treasury breaks lower and DOC’s next guidance is maintained. The thesis is DOC-specific operating resilience plus duration; exit if DOC underperforms VNQ by 5% after a favorable rate move.
• If Treasury yields rise materially from current levels, consider a tactical DOC short versus long XLV rather than an outright healthcare short. XLV retains defensive healthcare exposure while DOC bears the more direct valuation and refinancing sensitivity; reassess at earnings or if the 10-year reverses lower.
• Monitor biotech capital-markets activity and disclosed lab leasing/renewal metrics as a 6-18 month signal. A sustained recovery in biotech financing and positive lab absorption would support upgrading DOC relative to office-oriented REIT peers; absent that evidence, avoid assigning a premium multiple solely to the dividend yield.